

Continuation of U.S.S.N. 09/661,836  
Filed: December 4, 2001  
**PRELIMINARY AMENDMENT**  
Express Mail Label No.: EL 639 985 041 US  
Date of Deposit: December 4, 2001

The claims have been amended to incorporate the limitations of claim 9 into the independent claims.

Respectfully submitted,



---


Patrea L. Pabst  
Reg. No. 31,284

Date: December 4, 2001

HOLLAND & KNIGHT LLP  
2000 One Atlantic Center  
1201 West Peachtree Street, N.E.  
Atlanta, Georgia 30309-3400  
(404) 817-8473 (Telephone)  
(404) 817-8588 (Fax)

**Marked-Up Version of Amended Claims  
Pursuant to 37 C.F.R. § 1.121(c)(1)(ii)**


1. (amended) A pharmaceutical composition [for treating or preventing mucositis] comprising an effective amount of a poorly absorbed tetracycline in the form of a polyvalent metal ion complex in a carrier for topical administration [to the mucosa] wherein less than 10% of the tetracycline is absorbed into the systemic circulation when topically administered.
2. The composition of claim 1 wherein the tetracycline is selected based on poor oral absorption from the group consisting of tetracyclines defined by the following structure:



wherein R<sub>1</sub>-R<sub>5</sub> may be a hydrogen atom, a halogen atom, a hydroxyl group, or any other organic composition comprising from 1-8 carbon atoms and optionally include a heteroatom such as nitrogen, oxygen, in linear, branched, or cyclic structural formats.

3. The composition of claim 2 wherein R<sub>1</sub> and R<sub>2</sub> are hydrogen or a hydroxyl group; R<sub>3</sub> is hydrogen or a methyl group; R<sub>4</sub> is a hydrogen atom, a halogen, or a nitrogen containing entity; and R<sub>5</sub> is a hydrogen atom, or nitrogen containing ring structure.

4. The composition of claim 2 wherein the tetracycline is modified by substitution of H at carbon 9 by a substituted amido group.
5. The composition of claim 2 wherein the tetracycline is modified at any of positions 1 through 4 and 10 through 12.
6. The composition of claim 2 having the following structure:



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> can be H, C1-C3 alkyl, phenyl, and aryl groups; and

wherein X is an H, alkyl, alkoxy, phenoxy, aryloxy, amino group, amide, acyl, and halo group; and pharmaceutically acceptable salts thereof.

7. The composition of claim 6 wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are H; wherein R<sup>3</sup> is CH<sub>3</sub>; and wherein X is a chloro group.

8. The composition of claim 1 wherein the carrier for topical administration to the mucosa of the oral cavity and gastro-intestinal tract is selected from the group consisting of a mouthwash, lozenge, tablet, paste and gel.

9. The composition of claim 1 wherein the carrier for topical administration comprises the tetracycline coated onto or encapsulated into a carrier selected from the group consisting of powders, pellets, microcapsules, liposomes, and emulsions.

10. The composition of claim 9 wherein the tetracycline is formulated as a dry powder.

11. The composition of claim 1 wherein less than 10% of the tetracycline is absorbed into the systemic circulation when topically administered to the mouth and then swallowed.


12. The composition of claim 8 wherein the tetracycline is in the form of a polyvalent metal ion complex.

13. The composition of claim 12 wherein the polyvalent metal ion is calcium or magnesium.

14. The composition of claim 1 wherein the tetracycline is formulated to be topically administered to the mucosa as an aerosol.

15. (amended) A method for treating a patient in need thereof comprising administering to the patient an effective amount of a poorly absorbed tetracycline in the form of a polyvalent metal ion complex in a carrier for topical administration [to the mucosa] wherein less than 10% of the tetracycline is absorbed into the systemic circulation when topically administered.


16. The method of claim 15 wherein the tetracycline is selected based on poor absorption from the group consisting of tetracyclines defined by the following structure:



wherein R<sub>1</sub>-R<sub>5</sub> may be a hydrogen atom, a halogen atom, a hydroxyl group, or any other organic composition comprising from 1-8 carbon atoms and optionally include a heteroatom such as nitrogen, oxygen, in linear, branched, or cyclic structural formats.

17. The method of claim 15 wherein the tetracycline is selected from the group consisting of compounds with the formula wherein R<sub>1</sub> and R<sub>2</sub> are hydrogen or a hydroxyl group; R<sub>3</sub> is hydrogen or a methyl group; R<sub>4</sub> is a hydrogen atom, a halogen, or a nitrogen containing entity and R<sub>5</sub> is a hydrogen atom, or nitrogen containing ring structure, compounds wherein the tetracycline is modified at any of positions 1 through 4 and 10 through 12, and compounds wherein the tetracycline is modified by substitution of H at carbon 9 by a substituted amido group.

18. The method of claim 16 wherein the tetracycline has the following structure:



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> can be H, C1-C3 alkyl, phenyl, and aryl groups; and  
wherein X is an H, alkyl, alkoxy, phenoxy, aryloxy, amino group, amide, acyl, and halo group; and pharmaceutically acceptable salts thereof.

19. The method of claim 18 wherein the tetracycline is meclocycline,  
wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are H;  
wherein R<sup>3</sup> is CH<sub>3</sub>; and wherein X is a chloro group.

20. The method of claim 15 wherein the carrier for topical administration to the mucosa of the oral cavity and gastro-intestinal tract is selected from the group consisting of a mouthwash, lozenge, tablet, paste and gel.

21. The method of claim 15 wherein the carrier for topical administration comprises the tetracycline coated onto or encapsulated into a carrier selected from the group consisting of powders, pellets, microcapsules, liposomes, and emulsions, comprising suspending or dissolving the tetracycline and carrier in a liquid for administration of the tetracycline to the patient.

22. The method of claim 15 wherein the tetracycline is administered daily starting at least one day before the patient is treated with radiation or chemotherapy.

23. The method of claim 15 wherein the patient is treated between one and six times daily.

24. (amended) A method for making a composition for treating a patient to prevent or treat mucositis comprising making a formulation for topical administration [to the mucosa] of an effective amount of a tetracycline in the form of a polyvalent metal ion complex which has less than 10% bioavailability when orally administered.

姓名	性别	年龄	籍贯	职业	住址	电话	备注
王德胜	男	45	山东	教师	北京路123号	1234	
李秀英	女	38	河北	护士	文化路45号	5678	
张国强	男	52	河南	工人	工业路78号	9012	
刘小红	女	28	江苏	医生	健康路34号	3456	
陈为民	男	60	浙江	农民	农村路56号	7890	
赵大刚	男	35	湖北	工程师	科技路89号	2345	
孙丽娟	女	42	安徽	会计	商业路101号	6789	
周志远	男	58	江西	教授	大学路234号	1011	
吴小芳	女	30	福建	记者	新闻路567号	4321	
郑长龙	男	48	四川	干部	政府路890号	9876	
黄雅婷	女	25	广东	学生	学校路1234号	5432	
徐建国	男	55	广西	工人	工厂路5678号	1122	
马小梅	女	33	湖南	教师	学校路9012号	3344	
周大伟	男	40	陕西	工程师	技术路4567号	7788	
李翠兰	女	36	山西	护士	医院路8901号	2233	
张为民	男	50	甘肃	干部	机关路1234号	5566	
刘小华	女	27	云南	学生	大学路5678号	9900	
陈国强	男	53	贵州	工人	工厂路9012号	1122	
赵小红	女	31	海南	教师	学校路3456号	4455	
孙长龙	男	46	重庆	工程师	技术路7890号	6677	
周雅婷	女	29	四川	护士	医院路1234号	8899	
徐建国	男	51	湖北	干部	机关路5678号	2233	
马小芳	女	34	湖南	学生	大学路9012号	5566	
周大刚	男	43	广西	工人	工厂路3456号	7788	
李翠娟	女	37	山西	教师	学校路7890号	9900	
张为民	男	54	甘肃	工程师	技术路1234号	1122	
刘小梅	女	26	云南	护士	医院路5678号	3344	
陈国强	男	56	贵州	干部	机关路9012号	5566	
赵小红	女	32	海南	学生	大学路3456号	7788	
孙长龙	男	47	重庆	工人	工厂路7890号	9900	
周雅婷	女	30	四川	教师	学校路1234号	1122	
徐建国	男	52	湖北	工程师	技术路5678号	3344	
马小芳	女	35	湖南	护士	医院路9012号	5566	
周大刚	男	44	广西	干部	机关路3456号	7788	
李翠娟	女	38	山西	学生	大学路7890号	9900	
张为民	男	57	甘肃	工人	工厂路1234号	1122	
刘小梅	女	27	云南	教师	学校路5678号	3344	
陈国强	男	59	贵州	护士	医院路9012号	5566	
赵小红	女	33	海南	干部	机关路3456号	7788	
孙长龙	男	48	重庆	学生	大学路7890号	9900	
周雅婷	女	31	四川	工人	工厂路1234号	1122	
徐建国	男	53	湖北	教师	学校路5678号	3344	
马小芳	女	36	湖南	工程师	技术路9012号	5566	
周大刚	男	45	广西	护士	医院路3456号	7788	
李翠娟	女	39	山西	干部	机关路7890号	9900	
张为民	男	60	甘肃	学生	大学路1234号	1122	
刘小梅	女	28	云南	工人	工厂路5678号	3344	
陈国强	男	61	贵州	教师	学校路9012号	5566	
赵小红	女	34	海南	工程师	技术路3456号	7788	
孙长龙	男	49	重庆	护士	医院路7890号	9900	
周雅婷	女	32	四川	干部	机关路1234号	1122	
徐建国	男	54	湖北	学生	大学路5678号	3344	
马小芳	女	37	湖南	工人	工厂路9012号	5566	
周大刚	男	46	广西	教师	学校路3456号	7788	
李翠娟	女	40	山西	工程师	技术路7890号	9900	
张为民	男	62	甘肃	护士			



# FORMULATIONS FOR TREATING OR PREVENTING MUCOSITIS

## Cross-Reference to Related Applications

5     This application is a continuation of pending prior application U.S. Serial  
    No. 09/661,836 filed September 14, 2000, which claims priority to U.S. Serial  
    No. 60/153,892 filed September 14, 1999.

## **Field of the Invention**

The present application relates generally to formulations containing a tetracycline that are useful for treating or preventing mucositis.

10     [This application claims priority to U.S.S.N. 60/153,892 filed September 14, 1999.]

## **Background of the Invention**

Mucositis is a dose-limiting side effect of cancer therapy and bone marrow transplantation and is not adequately managed by current treatment  
15     (Sonis, 1993a, "Oral Complications," in: *Cancer Medicine*, pp. 2381-2388, Holand et al.; Eds., Lea and Febiger, Philadelphia; Sonis, 1993b, "Oral Complications in Cancer Therapy," In: *Principles and Practice of Oncology*, pp. 2385-2394, De Vitta et al., Eds., J. B. Lippincott, Philadelphia). Oral mucositis is found in almost 100% of patients receiving radiotherapy for head and neck  
20     tumors, in about 40% of patients receiving chemotherapy, and in about 90% of children with leukemia (Sonis, 1993b, supra). Complications related to oral mucositis, though varying in the different patient populations, generally include pain, poor oral intake with consequent dehydration and weight loss, and systemic infection with organisms originating in the oral cavity leading to  
25     septicemia (Sonis, 1993b; U.S. patent No. 6,025,326 to Steinberg et al.). In addition to the oral cavity, mucositis may also affect other parts of the gastrointestinal tract.

A variety of approaches to the treatment of oral mucositis and associated oral infections have been tested with limited success. For example, the use of an

**Clean Copy of Amended Specification Page 1**  
**Pursuant to 37 C.F.R. § 1.121(b)(1)(ii)**

1002402 430404  
Page 1 of 1

# FORMULATIONS FOR TREATING OR PREVENTING MUCOSITIS

## Cross-Reference to Related Applications

This application is a continuation of pending prior application U.S. Serial  
5 No. 09/661,836 filed September 14, 2000, which claims priority to U.S. Serial  
No. 60/153,892 filed September 14, 1999.

## Field of the Invention

The present application relates generally to formulations containing a  
tetracycline that are useful for treating or preventing mucositis.


## 10 Background of the Invention

Mucositis is a dose-limiting side effect of cancer therapy and bone  
marrow transplantation and is not adequately managed by current treatment  
(Sonis, 1993a, "Oral Complications," in: *Cancer Medicine*, pp. 2381-2388,  
Holand et al.; Eds., Lea and Febiger, Philadelphia; Sonis, 1993b, "Oral  
15 Complications in Cancer Therapy," In: *Principles and Practice of Oncology*, pp.  
2385-2394, De Vitta et al., Eds., J. B. Lippincott, Philadelphia). Oral mucositis  
is found in almost 100% of patients receiving radiotherapy for head and neck  
tumors, in about 40% of patients receiving chemotherapy, and in about 90% of  
children with leukemia (Sonis, 1993b, supra). Complications related to oral  
20 mucositis, though varying in the different patient populations, generally include  
pain, poor oral intake with consequent dehydration and weight loss, and  
systemic infection with organisms originating in the oral cavity leading to  
septicemia (Sonis, 1993b; U.S. patent No. 6,025,326 to Steinberg et al.).  
In addition to the oral cavity, mucositis may also affect other parts of the gastro-  
25 intestinal tract.

A variety of approaches to the treatment of oral mucositis and associated  
oral infections have been tested with limited success. For example, the use of an  
allopurinol mouthwash, an oral sucralfate slurry, and pentoxifyline were  
reported in preliminary studies to result in a decrease in mucositis. Subsequent

**Clean Copy of Amended Claims**  
**Pursuant to 37 C.F.R. § 1.121(c)(1)(i)**

1. (amended) A pharmaceutical composition comprising an effective amount of a poorly absorbed tetracycline in the form of a polyvalent metal ion complex in a carrier for topical administration wherein less than 10% of the tetracycline is absorbed into the systemic circulation when topically administered.
2. The composition of claim 1 wherein the tetracycline is selected based on poor oral absorption from the group consisting of tetracyclines defined by the following structure:




wherein R<sub>1</sub>-R<sub>5</sub> may be a hydrogen atom, a halogen atom, a hydroxyl group, or any other organic composition comprising from 1-8 carbon atoms and optionally include a heteroatom such as nitrogen, oxygen, in linear, branched, or cyclic structural formats.

3. The composition of claim 2 wherein R<sub>1</sub> and R<sub>2</sub> are hydrogen or a hydroxyl group; R<sub>3</sub> is hydrogen or a methyl group; R<sub>4</sub> is a hydrogen atom, a

halogen, or a nitrogen containing entity; and  $R_5$  is a hydrogen atom, or nitrogen containing ring structure.

4. The composition of claim 2 wherein the tetracycline is modified by substitution of H at carbon 9 by a substituted amido group.
5. The composition of claim 2 wherein the tetracycline is modified at any of positions 1 through 4 and 10 through 12.
6. The composition of claim 2 having the following structure:



wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ , and  $R^8$  can be H, C1-C3 alkyl, phenyl, and aryl groups; and

wherein X is an H, alkyl, alkoxy, phenoxy, aryloxy, amino group, amide, acyl, and halo group; and pharmaceutically acceptable salts thereof.

7. The composition of claim 6 wherein  $R^1$ ,  $R^2$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ , and  $R^8$  are H;

wherein  $R^3$  is  $CH_3$ ; and wherein X is a chloro group.

8. The composition of claim 1 wherein the carrier for topical administration to the mucosa of the oral cavity and gastro-intestinal tract is selected from the group consisting of a mouthwash, lozenge, tablet, paste and gel.

9. The composition of claim 1 wherein the carrier for topical administration comprises the tetracycline coated onto or encapsulated into a carrier selected from the group consisting of powders, pellets, microcapsules, liposomes, and emulsions.

10. The composition of claim 9 wherein the tetracycline is formulated as a dry powder.

11. The composition of claim 1 wherein less than 10% of the tetracycline is absorbed into the systemic circulation when topically administered to the mouth and then swallowed.


12. The composition of claim 8 wherein the tetracycline is in the form of a polyvalent metal ion complex.

13. The composition of claim 12 wherein the polyvalent metal ion is calcium or magnesium.

14. The composition of claim 1 wherein the tetracycline is formulated to be topically administered to the mucosa as an aerosol.

15. (amended) A method for treating a patient in need thereof comprising administering to the patient an effective amount of a poorly absorbed tetracycline in the form of a polyvalent metal ion complex in a carrier for topical administration wherein less than 10% of the tetracycline is absorbed into the systemic circulation when topically administered.


16. The method of claim 15 wherein the tetracycline is selected based on poor absorption from the group consisting of tetracyclines defined by the following structure:



wherein R<sub>1</sub>-R<sub>5</sub> may be a hydrogen atom, a halogen atom, a hydroxyl group, or any other organic composition comprising from 1-8 carbon atoms and optionally include a heteroatom such as nitrogen, oxygen, in linear, branched, or cyclic structural formats.

17. The method of claim 15 wherein the tetracycline is selected from the group consisting of compounds with the formula wherein R<sub>1</sub> and R<sub>2</sub> are hydrogen or a hydroxyl group; R<sub>3</sub> is hydrogen or a methyl group; R<sub>4</sub> is a hydrogen atom, a halogen, or a nitrogen containing entity and R<sub>5</sub> is a hydrogen atom, or nitrogen containing ring structure, compounds wherein the tetracycline is modified at any of positions 1 through 4 and 10 through 12, and compounds wherein the tetracycline is modified by substitution of H at carbon 9 by a substituted amido group.

18. The method of claim 16 wherein the tetracycline has the following structure:



wherein  $R^1, R^2, R^3, R^4, R^5, R^6, R^7$ , and  $R^8$  can be H, C1-C3 alkyl, phenyl, and aryl groups; and

wherein X is an H, alkyl, alkoxy, phenoxy, aryloxy, amino group, amide, acyl, and halo group; and pharmaceutically acceptable salts thereof.

19. The method of claim 18 wherein the tetracycline is meclocycline,

wherein  $R^1, R^2, R^4, R^5, R^6, R^7$ , and  $R^8$  are H;

wherein  $R^3$  is  $CH_3$ ; and wherein X is a chloro group.

20. The method of claim 15 wherein the carrier for topical administration to the mucosa of the oral cavity and gastro-intestinal tract is selected from the group consisting of a mouthwash, lozenge, tablet, paste and gel.



21. The method of claim 15 wherein the carrier for topical administration comprises the tetracycline coated onto or encapsulated into a carrier selected from the group consisting of powders, pellets, microcapsules, liposomes, and emulsions, comprising suspending or dissolving the tetracycline and carrier in a liquid for administration of the tetracycline to the patient.
22. The method of claim 15 wherein the tetracycline is administered daily starting at least one day before the patient is treated with radiation or chemotherapy.
23. The method of claim 15 wherein the patient is treated between one and six times daily.
24. (amended) A method for making a composition for treating a patient to prevent or treat mucositis comprising making a formulation for topical administration of an effective amount of a tetracycline in the form of a polyvalent metal ion complex which has less than 10% bioavailability when orally administered.